Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 19/20 | 0.79 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13061979 | 0.90 | PTGES2 (0.76) | PTGES2 | |
| SCHEMBL3774804 | 0.88 | PTGES2 (1.00) | PTGES2 | |
| SCHEMBL3774801 | 0.88 | PTGES2 (1.00) | PTGES2 | |
| SCHEMBL3776776 | 0.86 | PTGES2 (1.00) | PTGES2 | |
| SCHEMBL3776779 | 0.86 | PTGES2 (1.00) | PTGES2 | |
| SCHEMBL3780942 | 0.86 | PTGES2 (1.00) | PTGES2 | |
| SCHEMBL3780936 | 0.86 | PTGES2 (1.00) | PTGES2 | |
| SCHEMBL3776726 | 0.85 | PTGES2 (1.00) | PTGES2 | |
| SCHEMBL3776732 | 0.85 | PTGES2 (1.00) | PTGES2 | |
| SCHEMBL3784003 | 0.84 | PTGES2 (1.00) | PTGES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331321-A1 | Bis-(Sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| US-20090163586-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 205 | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163586-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 205 | PTGER1, SULT2A1, SULT1E1 | PTGES2 30/4885CA1 3346/4885CA2 2435/4885 |
| US-20100331321-A1 | Bis-(Sulfonylamino) derivatives for use in therapy | PTGER1, SULT2A1, SULT1E1 | PTGES2 25/4885CA1 3319/4885CA2 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.